About Xcell Therapeutics
Xcell Therapeutics is a company based in Seoul (South Korea) founded in 2015.. The company has 68 employees as of December 31, 2024. Xcell Therapeutics offers products and services including CellCor™ and Exosome Isolation Device. Xcell Therapeutics operates in a competitive market with competitors including Alnylam, Dicerna Pharmaceuticals, Silence Therapeutics, BioLife Solutions and DTx Pharma, among others.
- Headquarter Seoul, South Korea
- Employees 68 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Xcell Therapeutics, Inc.
-
Annual Revenue
$1.31 M (USD)72.11as on Dec 31, 2024
-
Net Profit
$-6.47 M (USD)-2.83as on Dec 31, 2024
-
EBITDA
$-5.21 M (USD)-5.12as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
68
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Xcell Therapeutics
Xcell Therapeutics is a publicly listed company on the KRX with ticker symbol 373110 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Xcell Therapeutics
Xcell Therapeutics offers a comprehensive portfolio of products and services, including CellCor™ and Exosome Isolation Device. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Serum-free media for optimal cell culture in regenerative therapies
Device for isolating exosomes in research and medical applications
Funding Insights of Xcell Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Xcell Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Xcell Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xcell Therapeutics Comparisons
Competitors of Xcell Therapeutics
Xcell Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Dicerna Pharmaceuticals, Silence Therapeutics, BioLife Solutions and DTx Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Drugs are developed using RNA interference technology platform.
|
|
| domain | founded_year | HQ Location |
RNA therapeutics for hematology and cardiovascular diseases are developed.
|
|
| domain | founded_year | HQ Location |
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
|
| domain | founded_year | HQ Location |
RNA-based therapeutics are developed for personalized health treatments.
|
|
| domain | founded_year | HQ Location |
Developer of human mesenchymal stem cells and extracellular vesicles
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Xcell Therapeutics
Frequently Asked Questions about Xcell Therapeutics
When was Xcell Therapeutics founded?
Xcell Therapeutics was founded in 2015.
Where is Xcell Therapeutics located?
Xcell Therapeutics is headquartered in Seoul, South Korea.
Who is the current CEO of Xcell Therapeutics?
Uri Uiil Lee is the current CEO of Xcell Therapeutics.
How many employees does Xcell Therapeutics have?
As of Dec 31, 2024, the latest employee count at Xcell Therapeutics is 68.
What is the annual revenue of Xcell Therapeutics?
Annual revenue of Xcell Therapeutics is $1.31M as on Dec 31, 2024.
What does Xcell Therapeutics do?
Xcell Therapeutics was founded in 2015 in Seoul, South Korea, within the biotechnology sector focused on regenerative medicine. Proprietary serum-free media, such as CellCor SFD MSCa fully defined optionand CellCor CD MSCa chemically defined variantare produced for cell culture applications. These products support pharmaceutical solutions in regenerative therapies, with operations centered on advancing cell-based treatments.
Who are the top competitors of Xcell Therapeutics?
Xcell Therapeutics's top competitors include Alnylam, Silence Therapeutics and Dicerna Pharmaceuticals.
What products or services does Xcell Therapeutics offer?
Xcell Therapeutics offers CellCor™ and Exosome Isolation Device.
Is Xcell Therapeutics publicly traded?
Yes, Xcell Therapeutics is publicly traded on KRX under the ticker symbol 373110.
What is Xcell Therapeutics's ticker symbol?
The ticker symbol of Xcell Therapeutics is 373110 on KRX.